Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Mary H. May"'
Publikováno v:
Arzneimittelforschung. 52:45-52
Mycobacterium avium growth in cultured human macrophages is influenced by serum lipids, transferrin and iron levels. Iron-saturated transferrin enhances M. avium growth, whereas apotransferrin inhibits mycobacterial replication. The ability of iron c
Autor:
George G. Zhanel, Shinjiro Hashimoto, K. Kyriakis, Isola, A.F. Mentis, B. Joly, Atsushi Saito, Yasuaki Osadd, Ross J. Davidson, Arcangelo, A. Quaglietta, Richard Greenberg, Antonio, Kyuichi Matsubayashi, G. Gialdroni Grassi, Mary H. May, S. Betti, K.D. Bremm, Alfred J. Crowle, R. Di Gianfilippo, K.G. Metzger, Martínez Díaz, Gómez Barrio, A. Tsakris, Daryl J. Hoban, Robert H. K. Eng, George S. Douvas, Hishama Saldin, A. Spadano, Sung Kim, P. Accorsi, U. Petersen, J. Rodríguez, A. Piergallini, M. Dell, R. Endermann, R. Cluzel, J. Atienza, Charles E. Cherubin, C. Jallat, Jingoro Shimada, Hussain Qadri, A. Recchia, J.A. Escario, Diane M. Citron, Sharon M. Smith, Kenneth Yen, Ellie J. C. Goldstein, Kumi Yoshida, Osamu Sakai, A. Fietta, C. Mastrangelo, P. Boeri, C. Forestier, A. Iacone, Saleh R. Al-Ballaa, D. Natale, Yoshio Ueno, Kohya Shiba, Lindsay E. Nicolle, N.J. Legakis, Joanne Crampton, L.S. Tzouvelekis, A. Darfeuille-Michaud, C. Ochoa, A. Herrero, Masaki Yoshida, E. Tzelepi, G. Fioritoni, G. Torlontano, M.L. Colombo, C. Merlini
Publikováno v:
Chemotherapy. 38:I-VI
Publikováno v:
Chemotherapy. 38:410-419
Chlorpromazine (CPZ) is one of several phenothiazines known to have antimicrobial properties. It can inhibit mycobacteria, and was reported in the early literature to improve tuberculosis clinically. CPZ was tested here for its ability to inhibit the
Autor:
J Richard Pearson, George S. Douvas, Mary H. May, Norma Tsuchida, Elaine T. Lam, Leann Miller
Publikováno v:
The Journal of infectious diseases. 170(5)
The growth of Mycobacterium avium 7497, serovar 4, in cultured human macrophages is enhanced by Fe3+ and serum lipids over 7 days. Iron (1-80 micrograms/mL) added to macrophages cultured in normal serum resulted in 10-fold increases in growth. If iro
Publikováno v:
Journal of Infectious Diseases. 167:857-857
Mycobacterium avium grows exponentially over 7 days in human macrophages when they are cultured in serumless medium. Normal serum inhibits this replication. When serum lipids were extracted using chloroform, the inhibitor was present in the lipid-fre
Publikováno v:
American Review of Respiratory Disease. 134:1052-1055
Pyrazinamide (PZA) is a unique antituberculosis drug because it is effective in vivo but not in mediums commonly used to culture tubercle bacilli. Consequently, it was employed to test the validity of an in vitro macrophage model of human tuberculosi
Publikováno v:
American Review of Respiratory Disease. 139:549-552
Pyrazinamide (PZA) is believed to be mycobactericidal in vivo. Because it is ineffective at neutral pH in vitro, it is thought to owe its in vivo activity at least partly to acting upon tubercle bacilli (TB) in the helpfully low pH of macrophage (MP)
Publikováno v:
Tubercle. 69:15-25
Isoniazid (INH) is said to inhibit tubercle bacilli equally well in vivo and in vitro , and to be mycobactericidal. Ceforanide (CEF) can inhibit tubercle bacilli in vitro but has been found ineffective clinically. These two drugs were tested against
Publikováno v:
American Review of Respiratory Disease. 137:1141-1146
Ofloxacin (OFL) is a new broad-spectrum drug with potentially valuable antimycobacterial activity. It was tested for ability to inhibit virulent tubercle bacilli (TB) and virulent Mycobacterium avium in cultured human macrophages (MP). The first-line
Serial oxygen dissociation curves were performed on blood units preserved in acid-citrate-dextrose (ACD), ACD-adenine, and ACD-adenine-inosine. Dividing blood from a single donor into two or more bags allowed direct comparison between preservatives.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128e7aa99a1932f1a8e723a9799f2528
https://europepmc.org/articles/PMC322222/
https://europepmc.org/articles/PMC322222/